Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Nutcracker Therapeutics has raised $167.0M in total funding. The most recent round was Series C. The last funding was announced in March 2022.
Nutcracker Therapeutics's investors include ARCH Venture Partners, Bluebird Ventures.
Nutcracker Therapeutics is headquartered in Emeryville, United States.
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Nutcracker Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nutcracker Therapeutics — Funding & Investors." VCBacked, March 14, 2022, https://www.vcbacked.co/company/nutcracker-therapeutics. Accessed October 1, 2026.
VCBacked. (2022). Nutcracker Therapeutics — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/nutcracker-therapeutics
{{cite web |title=Nutcracker Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nutcracker-therapeutics |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated